Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial)
Charing C. N. Chong(National University of Singapore), Paul B.S. Lai(Chinese University of Hong Kong), Eugene Lo(Chinese University of Hong Kong), Hon‐Ting Lok(Chinese University of Hong Kong), Kit F. Lee(Chinese University of Hong Kong), A. Fung(Chinese University of Hong Kong), Simon C.H. Yu(National Yang Ming Chiao Tung University), J. Hui(Chinese University of Hong Kong), Stephen L. Chan(Chinese University of Hong Kong), C. Chu(Chinese University of Hong Kong), Kelvin K. Ng(Chinese University of Hong Kong), John Wong(Chinese University of Hong Kong), Anthony Fong(Chinese University of Hong Kong), Yue S. Cheung(Chinese University of Hong Kong)
Cited by 73
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
|Hepatology|2002|2.6k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k